Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Alzheimer's Disease

  Free Subscription


Articles published in BMJ

Retrieve available abstracts of 14 articles:
HTML format



Single Articles


    August 2022
  1. DYER O
    Alzheimer's: Alleged image manipulation in seminal paper casts doubt on leading hypothesis of disease.
    BMJ. 2022;378:o2041.
    PubMed    


    April 2022
  2. DHANA K, Franco OH, Ritz EM, Ford CN, et al
    Healthy lifestyle and life expectancy with and without Alzheimer's dementia: population based cohort study.
    BMJ. 2022;377:e068390.
    PubMed     Abstract available


    March 2022
  3. DYER O
    Long delayed publication of data on Alzheimer's drug Aduhelm leaves questions unanswered.
    BMJ. 2022;376:o808.
    PubMed    


    January 2022
  4. LYTHGOE MP, Jenei K, Prasad V
    Regulatory decisions diverge over aducanumab for Alzheimer's disease.
    BMJ. 2022;376:e069780.
    PubMed    


    December 2021
  5. MAHASE E
    Aducanumab: European agency rejects Alzheimer's drug over efficacy and safety concerns.
    BMJ. 2021;375:n3127.
    PubMed    


    November 2021
  6. HAMILTON F, West C
    Predatory marriage: Doctors can help to spot and prevent this exploitation.
    BMJ. 2021;375:n2906.
    PubMed    


    September 2021
  7. VINOGRADOVA Y, Dening T, Hippisley-Cox J, Taylor L, et al
    Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases.
    BMJ. 2021;374:n2182.
    PubMed     Abstract available


    August 2021
  8. ILIFFE S, Manthorpe J
    Aducanumab, amyloid, and culture wars.
    BMJ. 2021;374:n2038.
    PubMed    


    July 2021
  9. DYER O
    FDA calls for investigation into industry influence during Alzheimer's drug approval.
    BMJ. 2021;374:n1778.
    PubMed    


  10. WALSH S, Merrick R, Milne R, Brayne C, et al
    Aducanumab for Alzheimer's disease?
    BMJ. 2021;374:n1682.
    PubMed    


    June 2021
  11. MAHASE E
    Three FDA advisory panel members resign over approval of Alzheimer's drug.
    BMJ. 2021;373:n1503.
    PubMed    


  12. MAHASE E
    FDA approves controversial Alzheimer's drug despite uncertainty over effectiveness.
    BMJ. 2021;373:n1462.
    PubMed    


    February 2021
  13. ACKLEY SF, Zimmerman SC, Brenowitz WD, Tchetgen Tchetgen EJ, et al
    Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis.
    BMJ. 2021;372:n156.
    PubMed     Abstract available


    October 2020
  14. SHI J, Sabbagh MN, Vellas B
    Alzheimer's disease beyond amyloid: strategies for future therapeutic interventions.
    BMJ. 2020;371:m3684.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: